Envarsus XR - (0.75 mg, 1 mg and 4 mg ; Extended-release Tablets)

Generic Name	Tacrolimus	Innovator	Veloxis
Dosage	0.75 mg, 1 mg and 4 mg ; Extended-release Tablets	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	ENVARSUS XR is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****** (*****)	*** / *********	*** **, ****	*******	****	******* *** **** *** *** ****
*** ******	** \ **	*** **, ****	*******	****	*** ****** *** ****
*****	** \ **	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events